New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation ...

Papillary thyroid cancer is the most prevalent type of thyroid cancer--with over 50,000 new cases per year in the United States. Around 80-90% of thyroid cancer cases are papillary cancer. Papillary ...

Today, we’re going to be focusing on differentiated thyroid cancer, but even with the diagnosis of differentiated thyroid cancer, there are multiple subtypes. Maybe I could ask Bryan to go into a ...

In an open-label, single-group, phase 2 study, we treated 93 patients who had progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer with 125 mg of ...

(2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on ...

Complete remission of differentiated thyroid cancer was more likely in patients treated with metformin than in the other 2 groups. Multivariate analysis results showed that extrathyroidal ...

More than one-third of patients treated for differentiated thyroid cancer reported elevated anxiety and more than 15% reported a high level of depression at an annual follow-up, according to study ...

Thyroid cancer starts in your thyroid gland, part of your endocrine system. ... Well-differentiated cancer cells have specialized structures and tend to grow and spread slowly.

Differentiated thyroid cancer (which is further broken down into subtypes of papillary, follicular, or Hurthle cell carcinoma) accounts for well over 90 percent of thyroid cancers.

Well-differentiated tumors (papillary and follicular thyroid cancer) are highly treatable and usually curable, notes the National Library of Medicine's PDQ summary.

Poorly differentiated thyroid cancer is uncommon, accounting for fewer than 5% of thyroid cancers. Poorly differentiated thyroid cancer is more clinically aggressive and can be challenging to treat.